iBio (IBIO) said late Monday it launched an underwritten public offering of pre-funded warrants to purchase common shares, along with accompanying series G and series H warrants, each representing rights to buy fractions of common shares or pre-funded warrants.
The company said it plans to use the net proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, progress other pipeline assets, and for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.